Leerink Partnrs Forecasts Stronger Earnings for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Leerink Partnrs upped their Q2 2025 earnings estimates for shares of Henry Schein in a research report issued to clients and investors on Monday, May 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $1.16 per share for the quarter, up from their prior forecast of $1.14. The consensus estimate for Henry Schein's current full-year earnings is $4.74 per share. Leerink Partnrs also issued estimates for Henry Schein's Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.81 EPS, FY2026 earnings at $5.28 EPS and FY2027 earnings at $5.70 EPS.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. During the same period in the prior year, the business earned $1.10 EPS. The firm's revenue was down .1% on a year-over-year basis.

A number of other brokerages have also recently weighed in on HSIC. Barrington Research reduced their target price on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Piper Sandler lowered their target price on Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. UBS Group cut their price objective on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. StockNews.com lowered shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Jefferies Financial Group raised their target price on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Six investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $79.30.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded down $0.21 during trading on Thursday, reaching $68.68. The company had a trading volume of 2,009,912 shares, compared to its average volume of 1,636,207. The firm's fifty day moving average is $67.59 and its 200 day moving average is $71.45. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The firm has a market capitalization of $8.41 billion, a PE ratio of 28.26, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49.

Institutional Trading of Henry Schein

Several hedge funds and other institutional investors have recently modified their holdings of HSIC. Palestra Capital Management LLC acquired a new stake in Henry Schein during the 4th quarter worth approximately $182,988,000. Lyrical Asset Management LP bought a new position in shares of Henry Schein in the 4th quarter valued at $126,655,000. Norges Bank acquired a new position in shares of Henry Schein during the 4th quarter worth $103,301,000. Steadfast Capital Management LP lifted its position in shares of Henry Schein by 254.2% during the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock worth $113,336,000 after buying an additional 1,175,408 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its stake in Henry Schein by 102.1% in the fourth quarter. Hudson Bay Capital Management LP now owns 1,465,007 shares of the company's stock valued at $101,378,000 after buying an additional 740,007 shares in the last quarter. Institutional investors own 96.62% of the company's stock.

Insider Buying and Selling

In related news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. 1.08% of the stock is currently owned by company insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.